GHB

# Research Output: GHB (Gamma-Hydroxybutyric Acid)

**PSX ID:** PSX-0202  
**Slug:** ghb  
**Research Date:** 2026-04-24  
**Substance Readiness:** Established (well-researched) — targeting ≥45 citations  
**Citations in registry:** 50

---

## Chemical Identity

**Verified via PubChem CID 10413:**

| Property | Value | Source |
|---|---|---|
| IUPAC name | 4-hydroxybutanoic acid | PubChem [Ref 1 basis — database lookup] |
| Molecular formula | C4H8O3 | PubChem CID 10413 |
| Molecular weight | 104.10 g/mol | PubChem CID 10413 |
| InChIKey | SJZRECIVHVDYJC-UHFFFAOYSA-N | PubChem CID 10413 |
| PubChem CID | 10413 | PubChem CID 10413 |
| CAS (free acid) | 591-81-1 | Web sources [web_retrieved] |
| CAS (sodium salt) | 502-85-2 | Web sources [web_retrieved] |
| SMILES | OC(=O)CCCO | Derived from structure (4-hydroxybutanoic acid) |

**Stereochemistry:** GHB (4-hydroxybutanoic acid) has no stereocenters in its structure; it is achiral. The free acid form is a racemic compound not applicable — the molecule has no chiral center. No published research was found specifically addressing GHB stereoisomers for pharmacological activity. The endogenous and exogenous forms are chemically identical.

**Physical properties:** GHB is a hygroscopic solid at room temperature. Its sodium salt (sodium oxybate, Xyrem) is a white crystalline powder that is highly soluble in water, due to two polar groups (hydroxyl and carboxyl) [web_retrieved]. A melting point for the free acid was not recovered in published peer-reviewed literature found in this search; the compound typically exists as a solution or sodium salt in clinical/commercial contexts. GHB does not undergo significant plasma protein binding [Ref 8].

**Brief seed data discrepancies:**
- Brief lists SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID as blank. All four are now confirmed: C4H8O3, 104.10, SJZRECIVHVDYJC-UHFFFAOYSA-N, CID 10413. **FLAG for DB update.**
- Brief lists IUPAC as blank but systematic name as "4-hydroxybutanoic acid" — PubChem confirms this is the correct IUPAC name. **FLAG for DB update.**
- Brief notes "Organic acid, Butyric acid, Γ-Hydroxy acid" as chemical class — confirmed accurate.

---

## Pharmacology

### Receptor Targets and Binding Affinity

GHB acts at two primary receptor systems, with the physiological significance of each being dose-dependent and the subject of ongoing research debate:

**1. GABA-B Receptor (Primary — Low Affinity)**

At therapeutic and recreational concentrations, GHB acts as a low-affinity agonist at GABA-B receptors. Felmlee et al. (2021 [Ref 1]) state that "pharmacological/toxicological effects [are] mainly due to GABA-B agonist effects." The Ki/EC50 of GHB at GABA-B receptors is in the millimolar range — GHB is a weaker GABA-B agonist than baclofen, requiring approximately 1–3 mM for significant activation in vitro. Kohlmeier et al. (2013 [Ref 5]) confirmed GABA-B receptor-mediated calcium rises in brainstem arousal nuclei (laterodorsal tegmentum, dorsal raphe), demonstrating that NCS-382 (putative GHB receptor antagonist) and HOCPCA (putative GHB receptor agonist) failed to block GHB-induced effects, indicating GABA-B — not GHB-specific receptors — mediates these actions. Carai et al. (2008 [Ref 7]) confirmed via animal models that GABA-B antagonists fully prevented GHB/GBL-induced hypothermia, motor incoordination, and sedation, while NCS-382 had no protective effect.

**2. GHB High-Affinity Binding Sites (Debated)**

GHB binds with nanomolar affinity to a distinct population of brain receptors, known as "GHB high-affinity sites," present for over three decades in radioligand binding studies. Absalom et al. (2012 [Ref 2]) provided the most compelling molecular identification: using photolinking and proteomics, they identified α4β1δ GABA-A receptors as GHB high-affinity targets, with **EC50 = 140 nM** in Xenopus oocyte expression systems. The δ-subunit was found essential for GHB potency and efficacy; α4F71L mutation abolished GHB but not GABA function, suggesting non-identical binding sites. However, Connelly et al. (2013 [Ref 4]) found **no evidence** that GHB (10 μM) induced GABA-A receptor current in ventrobasal thalamic neurons, dentate gyrus granule cells, or striatal medium spiny neurons in brain slice preparations, casting doubt on the physiological relevance of the α4β1δ target at native synapses. Bay et al. (2014 [Ref 3]) reviewed these conflicting data and concluded that the molecular identity of high-affinity GHB binding sites "has only recently begun" to be uncovered and remains incompletely established.

Ticku & Mehta (2008 [Ref 6]) characterized two binding site populations in rat brain using [³H]NCS-382 radioligand; NCS-382 was ~10× more potent than GHB at displacing radioligand, with Scatchard analysis revealing high-affinity and lower-affinity populations.

**3. Endogenous GHB Signaling System**

Maitre (1997 [Ref 16]) provided a foundational review: GHB is present in micromolar quantities throughout the brain, with highest concentrations in hippocampus, cortex, and dopaminergic structures (striatum, olfactory areas, frontal cortex, VTA/A9, A10, A12). Endogenous GHB is released in a Ca²⁺-dependent manner. At low concentrations, GHB-mediated stimulation of high-affinity receptors causes dopaminergic hyperpolarization and reduction of dopamine release; at high exogenous concentrations, GHB saturates and desensitizes these receptors, and GABA-B effects predominate, causing sedation and anesthesia.

**4. Downstream Signaling**

Coune et al. (2010 [Ref 12 basis]) showed that GHB at <50 μM (via the GHB receptor) inhibited forskolin-stimulated adenylate cyclase and elevated cytosolic Ca²+ via T-type calcium channels in NCB-20 neurons. These effects were blocked by NCS-382 but not by GABA-B antagonist CGP-55-845, suggesting GHB-receptor-specific signaling distinct from GABA-B. At concentrations >50 μM, these effects desensitized.

### Mechanism of Action Summary

The prevailing consensus (Felmlee et al. 2021 [Ref 1]; Dufayet et al. 2023 [Ref 9]; Busardò & Jones 2014 [Ref 15]) is:

- **Low doses (nM–low μM range):** Effects potentially mediated by high-affinity GHB binding sites (possibly α4βδ GABA-A receptors), causing dopamine modulation, mild sedation, and neuromodulation
- **Therapeutic/recreational doses (mM range):** GABA-B receptor activation predominates; produces sedation, hypnosis, muscle relaxation, respiratory depression, and dose-dependent CNS effects
- **Overdose (>100 mg/L plasma):** Profound GABA-B agonism; respiratory depression, coma, and potentially death

### Pharmacokinetics (Human Data)

Primary human PK data comes from Palatini et al. (1993 [Ref 8]), Dufayet et al. (2023 [Ref 9]), and Busardò & Jones (2014 [Ref 15]):

| Parameter | Value | Source |
|---|---|---|
| Route | Oral (primary) | [Ref 8, Ref 9] |
| Absorption onset | 5–45 min | [Ref 9] |
| Tmax (Cmax) | 20–40 min | [Ref 15] |
| Volume of distribution | 0.49 ± 0.9 L/kg | [Ref 9] |
| Plasma half-life | 20–60 min | [Ref 9] |
| Plasma protein binding | Not significant | [Ref 8] |
| Urinary excretion | 1–5% of dose | [Ref 15] |
| Detection window (blood) | ~6 hours | [Ref 9] |
| Detection window (urine) | ~10 hours | [Ref 9] |
| Endogenous levels | 0.5–1.0 mg/L in brain; serum 0.62–3.24 mg/L | [Ref 15, Ref 21] |

**Nonlinear kinetics:** Palatini et al. (1993 [Ref 8]) demonstrated in a 3-dose crossover study (12.5, 25, 50 mg/kg) in 8 healthy males that AUC increased disproportionately with dose — both oral absorption and elimination are capacity-limited processes. This explains the dramatically steep dose-response curve observed clinically.

**Blood-brain barrier transport:** Bhattacharya & Boje (2004 [Ref 18]) demonstrated that GHB crosses the BBB via monocarboxylate transporter 1 (MCT1); high-capacity, low-affinity kinetics (Vmax = 709 nmol/min/g, Km = 11.0 mM). This saturable transport system is a key determinant of brain exposure. Dave et al. (2017 [Ref 22]) developed a physiologically-based PK/PD model incorporating MCT1-mediated renal reabsorption, hepatic metabolism, and brain uptake. Felmlee et al. (2017 [Ref 34]) further demonstrated tissue-specific nonlinear GHB distribution (liver, kidney, heart, brain) consistent with MCT1 and MCT4 involvement.

**Metabolism:** Zhang et al. (2012 [Ref 40]) characterized GHB hepatic metabolism in perfused rat livers using metabolomics and mass isotopomer analysis. Multiple pathways identified:
1. Citric acid cycle entry via oxidation to succinic semialdehyde → succinate (primary pathway)
2. Substrate cycle between GHB and γ-aminobutyrate (GABA) via succinic semialdehyde
3. β-oxidation → glycolyl-CoA + acetyl-CoA
4. Degradation to acetyl-CoA via 4-phosphobutyryl-CoA

**CYP enzymes:** No published evidence found that GHB is a significant substrate or inhibitor of CYP450 enzymes. Vogel et al. (2017 [Ref 28 basis]) showed that the GHB receptor antagonist NCS-382 at 0.5 mM showed no CYP inhibition (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) — this is for the antagonist, not GHB itself. Kaufman & Nelson (1987 [Ref 42]) showed that valproate, salicylate, and phenylacetate inhibit GHB dehydrogenase, elevating brain GHB levels. Lyon et al. (2007 [Ref 17]) identified AKR7A2 as the major succinic semialdehyde reductase responsible for GHB biosynthesis in human neurons. The primary catabolic enzyme is a cytosolic NADP+-dependent oxidoreductase (GHB dehydrogenase).

**⚠️ FLAG:** No human CYP interaction data for GHB itself was located in the literature. Metabolism appears to proceed via non-CYP pathways (alcohol dehydrogenase family, NADP+-dependent oxidoreductases). Generation agent should note CYP involvement is not established.

---

## History

### Discovery and Early Research

GHB was **first synthesized in 1874**, though it was not investigated for pharmacological activity until the 20th century [web_retrieved — Wikipedia, multiple secondary sources including Fuller et al. 2004 [Ref 25]]. Fuller et al. (2004 [Ref 25]) state that GHB "was discovered in 1960" in the clinical/pharmaceutical sense — specifically, French biochemist **Henri Laborit** first synthesized and investigated GHB as a clinically relevant compound in 1960, intending it as a more BBB-permeable analogue of GABA for studying the inhibitory neurotransmitter system.

Laborit and colleagues investigated GHB for use as an **intravenous anesthetic agent** in the early 1960s. Galloway et al. (1997 [Ref 24]) note that GHB was "investigated as a tool for inducing absence seizures, for use as an anesthetic, and for treatment of narcolepsy, alcohol dependence and opiate dependence." GHB was marketed as an IV anesthetic in Europe starting in 1964 [web_retrieved].

Early clinical studies explored GHB in obstetric surgery, childbirth, and as an anxiolytic; anecdotal reports noted antidepressant and aphrodisiac effects [web_retrieved].

### Regulatory History

**1980s (United States):** GHB-containing products became widely available over-the-counter in health food stores, marketed for weight loss, bodybuilding (promoted as anabolic due to GH-releasing effects demonstrated by Van Cauter et al. 1997 [Ref 14]), and sleep. Fuller et al. (2004 [Ref 25]) note that "during the 1980s, easy access to GHB-containing products led to various unapproved uses."

**1990 onward:** GHB began being abused in the US for euphoric, sedative, and anabolic effects (Galloway et al. 1997 [Ref 24]). GHB gained notoriety as a "date-rape drug" due to rapid sedation, amnesia, and colorless/nearly odorless liquid form.

**2000 (US):** The **Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000** (Public Law 106-172) added GHB to Schedule I of the Controlled Substances Act [Ref 35]. The Act included a unique bifurcated scheduling provision: illicit GHB = Schedule I; FDA-approved sodium oxybate preparations = Schedule III.

**2001 (International):** GHB added to **Schedule IV of the UN Convention on Psychotropic Substances** [web_retrieved].

**2002 (US — FDA Approval):** Sodium oxybate (Xyrem®, Jazz Pharmaceuticals) was approved by the US FDA in **July 2002** for cataplexy in patients with narcolepsy, as an orphan drug (Fuller & Hornfeldt 2003 [Ref 26]; Thorpy 2005 [Ref 27]; Fuller et al. 2004 [Ref 25]). A restricted Risk Management Program (Xyrem Success Program) was established requiring centralized distribution, patient registry, and mandatory physician/patient education.

**2003 (UK):** GHB designated **Class C** controlled substance in June 2003 [web_retrieved; Lingford-Hughes et al. 2016 [Ref 31]].

**1990s onward (Italy and Austria):** Sodium oxybate marketed as **Alcover®** for alcohol withdrawal syndrome and alcohol dependence maintenance — the only EU countries with domestic approval for this indication (Guiraud & van den Brink 2024 [Ref 11]; van den Brink et al. 2018 [Ref 43]).

**2020 (US):** Low-sodium oxybate (Xywav®, Jazz Pharmaceuticals) approved for narcolepsy (EDS and cataplexy). FDA-approved for idiopathic hypersomnia in 2021 (Morse et al. 2023 [Ref 45]).

---

## Subjective Effects

Published descriptions of subjective effects come from controlled studies, clinical trials, and epidemiological reports:

**Low/recreational doses (plasma ~100 mg/L):**
- Euphoria and disinhibition (Busardò & Jones 2014 [Ref 15]; Dufayet et al. 2023 [Ref 9])
- Sedation and muscle relaxation
- Anxiolysis; loss of inhibition
- Amnesia (Doyno & White 2021 [Ref 38])
- Empathy enhancement and sociability (context of chemsex use — Giorgetti et al. 2017 [OpenAlex])
- Enhanced sexuality / sexual arousal (chemsex context)
- Drowsiness progressing to sleep

**Slow-wave sleep effects (controlled study):**
Van Cauter et al. (1997 [Ref 14]) demonstrated in a placebo-controlled crossover study (8 healthy men, 2.5–3.5g oral doses) that GHB at bedtime:
- Doubled growth hormone secretion via increased amplitude and duration of the first post-sleep-onset GH pulse
- Significantly increased sleep stage IV (slow-wave sleep)
- Transiently elevated prolactin and cortisol (not sustained)
- Did not alter thyrotropin or melatonin profiles

Bavato et al. (2025 [Ref 33]) — RCT in MDD patients (GHB 50 mg/kg vs. trazodone vs. placebo):
- GHB robustly prolonged slow-wave sleep (SWS)
- Increased total sleep time and sleep efficiency
- Reduced N1, N2, wake-after-sleep-onset
- Reduced next-day vigilance lapses vs. both comparators

**Higher doses (toxicity range):**
- Sedation → unconsciousness → coma
- Respiratory depression
- Nausea and vomiting (with risk of aspiration in impaired state)
- Motor incoordination

**Effect taxonomy validation:** The brief's effect taxonomy is largely consistent with published literature. Specific effects confirmed by publications:
- ✓ Sedation, muscle relaxation, disinhibition, cognitive euphoria — confirmed [Ref 1, Ref 9, Ref 15]
- ✓ Memory suppression (amnesia) — confirmed [Ref 12, Ref 38]
- ✓ Respiratory depression — confirmed [Ref 1, Ref 9]
- ✓ Seizure threshold reduction — confirmed in withdrawal context and at high doses [Ref 24]
- ✓ Sexual arousal enhancement — confirmed in chemsex context [Ref 31]
- ✓ Dream enhancement / dreaming effects — consistent with SWS promotion [Ref 14]
- ⚠️ "Stimulation" listed in brief body effects — this warrants editorial note; GHB is primarily a depressant. Low-dose GHB may cause brief dopaminergic activation (Maitre 1997 [Ref 16]) but "stimulation" as an effect category should be carefully contextualized.
- ⚠️ "Pupil dilation" listed — no published pharmacological mechanism found supporting this for GHB specifically. GABA-B agonism typically does not cause mydriasis. **FLAG for editorial review.**
- ⚠️ "Vasoconstriction" listed — no published mechanism found. **FLAG for editorial review.**

### Duration Data Assessment

Seed data (oral): onset 5–30 min, come-up 10–20 min, peak 45–90 min, offset 15–30 min, aftereffects 2–4 hours, total 1.5–2.5 hours.

Published PK data: Tmax = 20–40 min (Busardò & Jones 2014 [Ref 15]); absorption onset 5–45 min (Dufayet et al. 2023 [Ref 9]); plasma half-life 20–60 min [Ref 9]. The 1.5–2.5 hour total duration is broadly consistent with published PK data, though some users report effects lasting slightly longer, possibly reflecting the capacity-limited nonlinear kinetics producing individual variability. Dose data in the brief (threshold 0.5g, heavy 4+g) aligns with clinical and forensic literature showing euphoria at ~100 mg/L plasma and lethal risk at ~500 mg/L [Ref 15].

**No community feedback was submitted for dose/duration correction; seed data appears consistent with published evidence. No changes proposed.**

---

## Safety & Toxicity

### Toxic and Lethal Concentrations

- **Euphoria/disinhibition:** ~100 mg/L plasma (Busardò & Jones 2014 [Ref 15])
- **Death from cardiorespiratory depression:** ~500 mg/L plasma (Busardò & Jones 2014 [Ref 15])
- **Lethal dose (approximate):** ~60 mg/kg (Dufayet et al. 2023 [Ref 9]) — noted this is an approximate figure from a review; species for this LD50 value is **not specified** in Dufayet's review. **FLAG: LD50 source should be verified against primary animal toxicology data.**
- **Postmortem femoral blood in GHB intoxication deaths (n=37):** mean 637 mg/L, range 30–9,200 mg/L (Jones et al. 2018 [Ref 20])
- **Toxic dose note:** Brief states "doses above 10 grams are associated with a risk of death." This is broadly consistent with published data: at 10g (assuming ~70kg adult = ~143 mg/kg >> 60 mg/kg lethal threshold). However, the exact threshold is highly individual and depends on tolerance, co-ingested substances, and body weight. **⚠️ Safety-critical value — flag for verification.**

### Acute Toxicity Profile

Felmlee et al. (2021 [Ref 1]) and Dufayet et al. (2023 [Ref 9]) both describe the acute toxicity profile:
- Dose-dependent: sedation → respiratory depression → unconsciousness → coma → death
- Steep concentration-effect curve means small dose increments produce disproportionate CNS effects (due to nonlinear kinetics)
- Respiratory depression is the primary mechanism of death
- No pharmacological antidote exists; treatment is supportive (airway management, vital sign monitoring)
- Patients typically recover rapidly if airway maintained (short half-life of 20–60 min)
- Risk of aspiration pneumonia from vomiting while unconscious

Doyno & White (2021 [Ref 38]) note: "When any of these GABAergic drugs are used in high doses or with other sedative hypnotic agents, respiratory depression, coma, and death have occurred."

### Endogenous vs. Exogenous GHB in Forensic Context

Andresen et al. (2010 [Ref 21]) established that endogenous GHB in serum = 0.62–3.24 mg/L (mean 1.14 mg/L) and in urine = 0.64–4.20 mg/L (mean 1.21 mg/L), with cutoffs of 4 mg/L (serum) and 6 mg/L (urine) for identifying exogenous GHB ingestion. GBL and 1,4-BD are unscheduled precursors that are rapidly converted to GHB in vivo (t½ ~1 min), making GHB detectable regardless of which form was ingested (Dufayet et al. 2023 [Ref 9]).

### Organ Toxicity

No published evidence of direct hepatotoxicity, nephrotoxicity, or cardiac toxicity from GHB at recreational doses in the absence of overdose. Brief describes GHB as "safe and non-toxic when used responsibly" — this is broadly consistent with the literature: Guiraud & van den Brink (2024 [Ref 11]) note that in a pharmacovigilance database of >260,000 alcohol-dependent patients treated with sodium oxybate, "serious adverse events were rare" and main effects were "mild, such as dizziness and vertigo." The primary toxicity risk is dose-dependent acute CNS/respiratory depression.

**Cognitive effects (chronic use):** Amsterdam et al. (2022 [Ref 12]) conducted a systematic review of cognitive impairment from clinical and recreational GHB use, finding evidence of cognitive impairment at high doses (comatose state) and suggesting possible neurotoxic effects from chronic heavy recreational use, though evidence base was limited.

---

## Harm Reduction

### Key Harm Reduction Points (from published literature)

**Dose control:**
- The steep, nonlinear dose-response curve is a primary harm driver [Ref 8, Ref 1]. Small additional amounts can shift from euphoria to unconsciousness.
- Liquid GHB is commonly sold in variable concentrations, making dose measurement extremely unreliable.

**Alcohol interaction (LETHAL risk):**
- GHB combined with alcohol carries lethal risk through additive/synergistic CNS and respiratory depression [Ref 15, Ref 24, Ref 38]. The interaction is listed as **lethal** in the seed data, consistent with published literature. Carai et al. (2008 [Ref 7]) confirmed GABA-B receptor mediation of this CNS depression.

**Opioid interactions (LETHAL):**
- All opioids listed in the seed data (fentanyl, heroin, morphine, oxycodone, hydromorphone, etc.) carry **lethal** interaction risk via additive respiratory depression. This is consistent with pharmacological principles of combined CNS depressant effects.

**Stimulant interactions (UNKNOWN):**
- Several stimulants (amphetamine, MDMA, cocaine, methamphetamine) are listed as "unknown" severity. Ricci et al. (2021 [Ref 13]) note GHB is used in chemsex contexts often alongside stimulants; the masking of CNS depression by stimulants may encourage redosing, increasing overdose risk. No specific controlled interaction studies found in this search.

**Dissociative interactions (LETHAL):**
- Ketamine, PCP, MXE listed as lethal in seed data. Pharmacologically plausible (additive CNS depression) but specific case reports or controlled data were not retrieved in this search. **FLAG: Interaction severity for dissociatives should be verified against published case reports.**

**Detection:**
- Standard urine drug screens do not detect GHB; specialized GC-MS or immunoassay testing required (Andresen et al. 2010 [Ref 21]).
- Very short detection window (blood ~6h, urine ~10h) complicates forensic investigation of drug-facilitated assault [Ref 9, Ref 41].

**Precursors:**
- GBL (gamma-butyrolactone) and 1,4-BD (1,4-butanediol) are unscheduled in most jurisdictions but rapidly convert to GHB in vivo. Dufayet et al. (2023 [Ref 9]) review their equivalence; users may be unaware they are consuming GHB precursors.

**Chemsex context:**
- GHB is a primary chemsex drug (alongside methamphetamine and mephedrone) among MSM populations. Lingford-Hughes et al. (2016 [Ref 31]) note GHB/GBL use may reach 20% in some MSM communities. Chemsex use is associated with HIV and STI risk, multiple sexual partners, and condomless sex [Ref 36 basis].

**Contraindications (from seed data and literature):**
- Concurrent CNS depressants (opioids, benzodiazepines, alcohol, ketamine): LETHAL risk
- Concurrent GBL or 1,4-BD use: effectively double-dosing GHB
- Patients with SSADH deficiency: contraindicated (endogenous GHB already elevated)
- Pregnancy: no evidence-based guidelines; case report of withdrawal management in pregnancy (Joyce et al. 2024 [Ref 48])
- Succinic semialdehyde dehydrogenase deficiency: GHB accumulates endogenously; exogenous use would dramatically elevate levels

**Emergency response (supportive):**
- No antidote exists (Felmlee et al. 2021 [Ref 1]; Busardò & Jones 2014 [Ref 15])
- Recovery position to prevent aspiration
- Monitor airway, breathing, circulation
- GHB elimination is rapid (t½ 20–60 min) — patients may recover spontaneously if airway protected
- Hemodialysis or MCT transport inhibition are proposed investigational strategies (Bhattacharya & Boje 2004 [Ref 18])

---

## Tolerance & Dependence

### Tolerance Development

The brief states tolerance builds "within several days of continuous use" with full reset at "10.5 days." No specific published studies quantifying the exact tolerance development timeline in controlled studies were found. However:

- Galloway et al. (1997 [Ref 24]) noted that "prolonged use of high doses may lead to a withdrawal syndrome," implying tolerance development with repeated use
- Doyno & White (2021 [Ref 38]) state "chronic use of these GABAergic drugs can lead to significant withdrawal syndromes," consistent with physiological tolerance

The "10.5 day reset" in the brief: no published pharmacological study was found specifically establishing this timeline. **FLAG: tolerance timeline not confirmed against published primary sources. Likely derived from community consensus.**

### Dependence Liability

The seed data describes GHB as "moderately to highly physically and moderately psychologically addictive." This is consistent with published literature:
- Physical dependence is well-established [Ref 24, Ref 10, Ref 37]
- GHB use disorder characterized by compulsive use despite harm, poor treatment outcomes
- Relapse rates >60% within 3 months after detoxification (Beurmanjer et al. 2019 [Ref 28])
- GHB dependence is "a growing health problem in several western countries, especially the Netherlands" (Kamal et al. 2015 [Ref 49])

### Withdrawal Syndrome

Galloway et al. (1997 [Ref 24]) — the foundational case series — described GHB withdrawal as including **insomnia, anxiety, and tremor**, resolving in **3–12 days**. This is consistent with seed data's tolerance reset of 10.5 days.

More recent literature characterizes GHB withdrawal as potentially severe:
- Moitroux & Kestens (2023 [Ref 37]): Onset is more rapid than alcohol or benzodiazepine withdrawal; neuropsychiatric symptoms can be severe
- Wood et al. (2025 [Ref 10]): Withdrawal can be "potentially fulminant" with rapid progression from mild to severe; developed first GHB-specific withdrawal assessment scale
- Dijkstra et al. (2017 [Ref 30]): Benzodiazepines are first-line for detoxification; DeTiTap (pharmaceutical GHB titration and tapering) feasible and safe in 23 patients
- Siefried et al. (2023 [Ref 23]): Inpatient management data from Sydney — limited evidence on optimal medications

**Treatment:**
- Benzodiazepines: currently first-line (but inadequate for all cases)
- Baclofen (GABA-B agonist): promising as adjunct and relapse prevention (Beurmanjer et al. 2018 [Ref 29]; Kamal et al. 2015 [Ref 49]; Lingford-Hughes et al. 2016 [Ref 31])
- Pharmaceutical GHB tapering (DeTiTap): feasible in specialist settings [Ref 30]
- No FDA-approved or EMA-approved evidence-based protocol for GHB withdrawal

---

## Interactions

### Pharmacologically Characterized Interactions

**Alcohol/Ethanol — LETHAL:**
Both GHB and ethanol are CNS depressants acting on GABA systems (ethanol broadly; GHB specifically at GABA-B). Additive/synergistic respiratory depression and CNS depression. Busardò & Jones (2014 [Ref 15]) and Dufayet et al. (2023 [Ref 9]) explicitly state this is a high-lethality combination. Carai et al. (2008 [Ref 7]) demonstrated that GABA-B mediates sedative/lethal effects of GHB/GBL; ethanol would additively recruit the same system. Caputo & Bernardi (2010 [Ref 50]) note GHB "does not have significant interactions with ethanol that render it safe to use" — this refers specifically to therapeutic contexts suggesting pharmaceutical GHB may be used after drinking without additional interaction, but at recreational/overdose doses this distinction is moot.

**Baclofen — LETHAL:**
Baclofen is a GABA-B agonist. Combined with GHB (also GABA-B agonist), synergistic GABA-B activation would profoundly suppress CNS function. Seed data lists as **lethal** — pharmacologically well-justified. Lingford-Hughes et al. (2016 [Ref 31]) use baclofen therapeutically in GHB-dependent patients (controlled medical context), confirming the interaction requires careful clinical management.

**Opioids — LETHAL (multiple):**
All opioids listed (fentanyl, heroin, morphine, hydrocodone, oxycodone, methadone, tramadol, buprenorphine, etc.) — additive respiratory depression via different mechanisms (μ-opioid vs. GABA-B). No specific controlled interaction studies found, but the mechanism is clear and the risk is well-established in clinical toxicology literature. Duyno & White (2021 [Ref 38]) note combined sedative-hypnotics cause "respiratory depression, coma, and death."

**Ketamine, PCP, MXE, MXE, rolicyclidine — LETHAL:**
Listed as lethal in seed data. Dissociatives cause CNS depression via NMDA antagonism; combined with GHB's GABAergic depression, additive CNS/respiratory depression is plausible. No specific published studies on these pairings retrieved. **FLAG: not verified against specific primary sources.**

**2-Fluorodeschloroketamine — LETHAL:**
Novel dissociative; same mechanism concern as ketamine. No specific published data found. **FLAG: based on class extrapolation.**

**Stimulants (amphetamines, cocaine, MDMA, methamphetamine) — UNKNOWN:**
Seed data lists as "unknown." In chemsex contexts, GHB is commonly combined with stimulants. Ricci et al. (2021 [Ref 13]) note this is common but no specific interaction studies were found. The primary concern is stimulant masking of GHB's sedative effects, leading to overdosing. Pharmacological interactions are not expected to be directly lethal at recreational doses (opposite mechanisms), but the behavioral risk (uninhibited redosing) may be severe.

**GBL and 1,4-BD:**
These are GHB prodrugs; combining with GHB is effectively overdosing on GHB.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Date | Notes |
|---|---|---|---|---|
| United States | Controlled | Schedule I (illicit); Schedule III (Xyrem, Xywav) | 2000 (Schedule I); 2002 (Schedule III exception) | Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act [Ref 35] |
| United Kingdom | Controlled | Class C | June 2003 | [Ref 31, web_retrieved] |
| International (UN) | Controlled | Schedule IV Convention on Psychotropic Substances | 2001 | All EU member states bound |
| Italy | Prescription approved | Alcover® | 1990s | Approved for alcohol withdrawal/dependence maintenance |
| Austria | Prescription approved | Alcover® | 1990s | Approved for alcohol withdrawal/dependence maintenance |
| Canada | Controlled | Schedule III (CDSA) | 2000 | [web_retrieved] |
| Australia | Controlled | Schedule 8 (Prescription Only) / Prohibited | Controlled | Prohibited except pharmaceutical use [web_retrieved] |
| New Zealand | Controlled | Controlled | — | [web_retrieved] |

**Precursors:** GBL and 1,4-BD are not internationally scheduled (not subject to UN Convention controls), though some jurisdictions have domestic controls. This legal gap enables ongoing availability of GHB equivalents (Dufayet et al. 2023 [Ref 9]).

---

## Clinical Trials

Key completed and active trials (ClinicalTrials.gov):

| NCT | Title | Phase | Status | Condition | Sponsor |
|---|---|---|---|---|---|
| NCT00058955 | Physiological, Behavioral and Subjective Effects of Drugs (GHB) | Phase 1 | Completed | Sedative Abuse | Orphan Medical |
| NCT00066170 | Xyrem vs Modafinil vs Placebo in Narcolepsy Daytime Sleepiness | Phase 3 | Completed | Narcolepsy | Jazz Pharmaceuticals |
| NCT02221869 | Xyrem in Pediatric Narcolepsy with Cataplexy | Phase 3 | Completed | Narcolepsy with Cataplexy | Jazz Pharmaceuticals |
| NCT00087555 | Xyrem vs Placebo for Fibromyalgia | Phase 2 | Completed | Fibromyalgia | Jazz Pharmaceuticals |
| NCT00423605 | Xyrem Safety and Efficacy in Fibromyalgia | Phase 3 | Completed | Fibromyalgia | Jazz Pharmaceuticals |
| NCT04322214 | GHB and Cobicistat Pharmacokinetic Interactions | Phase 1 | Completed | HIV / PK Interactions | Fundación FLS, Spain |
| NCT04006925 | Sodium Oxybate for REM Sleep Behavior Disorder | Phase 4 | Completed | RBD / Parkinson's | Stanford University |
| NCT02055898 | SWS and Daytime Functioning in Chronic Fatigue Syndrome (SAFFE) | Phase 4 | Completed | CFS | Imperial College London |
| NCT03533114 | JZP-258 (Low-Sodium Oxybate) in Idiopathic Hypersomnia | Phase 3 | Completed | Idiopathic Hypersomnia | Jazz Pharmaceuticals |
| NCT06421532 | Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy | Phase 2 | Enrolling | Cerebral Amyloid Angiopathy | Leiden University Medical Center |
| NCT07077278 | LXB on Autonomic Symptoms in Idiopathic Hypersomnia with POTS | Phase 4 | Not Yet Recruiting | IH + POTS | Stanford University |

**Clinical trial context:**
- The Xyrem narcolepsy trials (NCT00066170, NCT02221869) established the clinical evidence base for FDA approval. Once-nightly sodium oxybate (LUMRYZ, NCT02720744 — REST-ON trial) was subsequently approved.
- Fibromyalgia trials (NCT00087555, NCT00423605) showed significant efficacy — Russell et al. (2011 [Ref 32]) reported 54–58% ≥30% pain reduction vs 35% placebo — but sodium oxybate was not approved for fibromyalgia.
- The NCT04322214 (cobicistat interaction) trial is clinically important: cobicistat and ritonavir (HIV medications) inhibit drug metabolism and can dramatically elevate GHB plasma concentrations in HIV patients using chemsex GHB/GBL — a recognized clinical safety concern (Adler et al. 2022 [Ref basis]).
- The cerebral amyloid angiopathy trial (NCT06421532) reflects emerging research on SWS augmentation to promote glymphatic amyloid clearance.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No feedback items to investigate or report.

---

## Gaps & Flags

### Safety-Critical Values Needing Verification

1. **⚠️ LETHAL DOSE:** The ~60 mg/kg lethal dose cited in Dufayet et al. (2023 [Ref 9]) is a review-level estimate. No primary animal LD50 study was retrieved in this search. Species for this value is unspecified in the Dufayet review. The generation agent should flag this value for editorial verification against primary toxicology data.

2. **⚠️ DOSE CEILING — "10g associated with death risk":** Brief states doses above 10g risk death. This is consistent with the ~60 mg/kg threshold (for a ~70kg adult, 10g = 143 mg/kg), but individual variability in tolerance is extreme. This value is not directly cited in a primary source in this research; it appears to be a derived estimate. **Flag as safety-critical; verify against case reports.**

3. **⚠️ INTERACTION SEVERITY — Dissociatives:** Seed data lists ketamine, PCP, MXE, rolicyclidine, and 2-fluorodeschloroketamine as "lethal." This classification is pharmacologically plausible (additive CNS depression) but no specific published controlled studies or case reports confirming lethality for these specific combinations were retrieved. **Flag as based on class extrapolation.**

4. **⚠️ INTERACTION SEVERITY — Stimulants listed as "unknown":** The behavioral risk of GHB + stimulant combinations (masked sedation leading to compulsive redosing and overdose) may be severe even if the direct pharmacodynamic interaction is not immediately lethal. Generation agent should address this nuance.

### Data Gaps (No Published Data Found)

5. **Tolerance reset timeline (10.5 days):** Not confirmed against a specific published primary source. Community consensus or clinical observation. Noted as unverified in this research.

6. **Specific GABA-B Ki for GHB:** The mM affinity range at GABA-B is well-established qualitatively, but a specific Ki value was not retrieved in a human receptor binding study. Animal/in vitro data used as proxy.

7. **CYP enzyme involvement:** No evidence that GHB is a CYP substrate or inhibitor. Metabolism appears to proceed via non-CYP oxidoreductases. The generation agent should state this explicitly rather than assuming CYP involvement.

8. **Melting point and detailed physical properties:** Melting point, pKa, specific solubility values not recovered from published PK literature. Sodium salt form is white powder, highly water-soluble; free acid form properties were not published in the papers retrieved.

9. **GHB stereochemistry:** GHB has no stereocenters and is achiral. No stereo-specific pharmacology research was found or relevant.

10. **"Pupil dilation" and "vasoconstriction" in effects taxonomy:** No published pharmacological mechanism supporting these specific effects for GHB was identified. GABA-B agonism does not typically cause mydriasis. These taxonomy entries should be flagged for editorial review.

11. **Stimulation as a body effect:** Brief lists "Stimulation" as a body effect. This is inconsistent with GHB's primary classification as a CNS depressant. Low-dose dopaminergic activation (Maitre 1997 [Ref 16]) may produce a brief stimulatory phase, but "stimulation" as a standalone effect category is potentially misleading. Recommend editorial note.

### Contradictions with Seed Data

12. **Chemical identity fields blank in brief:** PubChem confirmed formula (C4H8O3), weight (104.10), InChIKey (SJZRECIVHVDYJC-UHFFFAOYSA-N), CID (10413). These should be populated in DB.

13. **Primary ROA listed as "oral" only:** Published literature confirms oral as primary ROA. Rectal administration is used by some recreational users (particularly in chemsex) and is noted in European harm reduction literature, though no formal pharmacokinetic study in humans was found for rectal route. IV route is used in historical medical contexts. The "known ROAs" field in brief should potentially include rectal (community-reported) and IV (historical medical).

14. **Brief toxicity notes say GHB is "safe and non-toxic when used responsibly or medically":** This is partially accurate (well-tolerated at therapeutic doses) but somewhat misleading without the severe caveat about the narrow therapeutic index, steep dose-response, and lethality at higher doses. Generation agent should balance this characterization carefully.

---

## Source Quality Assessment

- **50 citations in registry** — meets ≥45 target for well-researched substance
- **Primary research papers:** 28 (api_verified)
- **Review articles / systematic reviews:** 15 (api_verified or web_retrieved)
- **Case reports:** 5
- **Government/regulatory sources:** 1 (web_retrieved)
- **Books/unverifiable:** 0
- **Key landmark papers:**
  - Galloway et al. 1997 (Addiction, 274 citations) — foundational dependence paper [Ref 24]
  - Van Cauter et al. 1997 (JCI, 233 citations) — GH and SWS stimulation [Ref 14]
  - Busardò & Jones 2014 (Current Neuropharmacology, 213 citations) — comprehensive PK/toxicology review [Ref 15]
  - Absalom et al. 2012 (PNAS) — α4βδ GABA-A as high-affinity GHB target [Ref 2]
  - Felmlee et al. 2021 (AAPS Journal) — comprehensive modern PK/PD/toxicology review [Ref 1]